Prostaglandin F2alpha given by continuous transcervical extra-amniotic infusion combined with intravenous oxytocin infusion for therapeutic termination of mid-trimester pregnancies.
Prostaglandin F2alpha administered by continuous transcervical extra-amniotic infusion, and supplemented with oxytocin, given intravenously, to induce therapeutic abortion during the second trimester in 50 cases. This method was successful in all cases and has the advantages of being technically simple and requiring only a small dose of prostaglandin. The main hazard is intrauterine infection, which can be prevented by preliminary bacteriological investigation of the cervix and appropriate prophylactic antibiotic therapy. Prostaglandins are not yet available in Australia for general medical use. Our experience with prostaglandin F2alpha administered in the manner described indicates that it has an important part to play in gynaecological therapy.
D000032:Abortion, Therapeutic / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000650:Amnion; D002584:Cervix Uteri; D004359:Drug Therapy, Combination; D005260:Female; D005738:Gas Gangrene / Q000209:etiology; D006801:Humans; D007263:Infusions, Parenteral; D010121:Oxytocin / Q000008:administration & dosage*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000009:adverse effects; D014591:Uterine Diseases / Q000209:etiology; D014592:Uterine Hemorrhage / Q000209:etiology
D011460:Prostaglandins F; D010121:Oxytocin